Literature DB >> 32383161

Early look at the future of healthcare during the COVID-19 pandemic.

M Abu Hilal1, M G Besselink2, D H L Lemmers1,2, M A Taylor3, A Triboldi1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32383161      PMCID: PMC7267408          DOI: 10.1002/bjs.11666

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


× No keyword cloud information.
Editor Amidst the COVID-19 pandemic, all efforts are now focusing on controlling and treating the disease and its far-reaching consequences. Several measures have been put in place, including shutdown of social and economic activities, mask protection and self-isolation when needed. Hospitals have been transformed into emergency assessment areas, medical and surgical COVID-19 wards, and busy intensive care units (ICUs). This has led to a rearrangement of the healthcare system, including suspension of purely elective surgery with the aim of saving ICU beds for COVID-19 patients. In the current situation, we have all witnessed the flexibilities of the system, especially the hard work and altruism of its healthcare providers. As providers of oncology surgery, it is our duty to focus on what the services will look like following the pandemic. Our aim should be to return to treating these patients, starting with the most urgent and life-threatening medical conditions, with the aim of re-establishing a full service as soon as possible. This planning and reflection should be made as early as possible in a collaborative approach between medical, managerial and logistic expertise based on local realities, available resources and patient needs. Clinicians and healthcare providers should have an important role in advising both policy-makers and the public on the need for caution before calling for a full return to normal activities. Ideally, this would be based on evidence, accumulated experience and professional wisdom. We would anticipate that if the agreed strategy will be a gradual return to normal activities, healthcare would be one of the first to begin, followed by economic, industrial, agricultural and educational systems. When given the green light, hospitals should start a gradual introduction of their elective activities. This can only take place when they can reduce the number of their committed hospital and ICU beds ‘at peak’ without affecting the quality of the COVID-19 services offered. At that stage only, a reintroduction can be initiated by prioritizing services with the most important and pressing clinical needs such as oncological care. At that stage, a careful assessment of COVID-19 status in admitted patients and healthcare providers is essential to ensure a low risk of transmission. As patients will require a wide range of services from radiology, endoscopy, intensive care and surgical services, offering a full range of services in completely COVID-19-free areas may be required. Each hospital's planning committee will need to be imaginative and creative with its reimplementation models. Strategies such as hospitals being divided into a number of wings or buildings, some dedicated to COVID-19 patients, and others to non-COVID-19 patients with separate entries, pathways and services, may be considered. It may be essential to identify separate teams dealing with COVID-19-negative or -positive patients to reduce cross-contamination risk. Establishing other models, such as identifying some hospitals to be dedicated to the chronic management of COVID-19, leaving other tertiary hospitals to deal with COVID-19-negative patients in clean environments, needs strategic solutions at wider levels.
  3 in total

1.  COVID-19 pandemic: perspectives on an unfolding crisis.

Authors:  A Spinelli; G Pellino
Journal:  Br J Surg       Date:  2020-03-23       Impact factor: 6.939

2.  Respiratory support for patients with COVID-19 infection.

Authors:  Silvio A Ñamendys-Silva
Journal:  Lancet Respir Med       Date:  2020-03-05       Impact factor: 30.700

3.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

  3 in total
  3 in total

1.  International Delphi Expert Consensus on Safe Return to Surgical and Endoscopic Practice: From the Coronavirus Global Surgical Collaborative.

Authors:  Horacio J Asbun; Mohammad Abu Hilal; Filipe Kunzler; Domenech Asbun; Jaap Bonjer; Kevin Conlon; Nicolas Demartines; Liane S Feldman; Salvador Morales-Conde; Andrea Pietrabissa; Aurora D Pryor; Christopher M Schlachta; Patricia Sylla; Eduardo M Targarona; Yolanda Agra; Marc G Besselink; Mark Callery; Sean P Cleary; Luis De La Cruz; Philippe Eckert; Chad Evans; Ho-Seong Han; Daniel B Jones; Tong Joo Gan; Daniel Koch; Keith D Lillemoe; Davide Lomanto; Jeffrey Marks; Brent Matthews; John Mellinger; William Scott Melvin; Eduardo Moreno-Paquentin; Claudio Navarrete; Timothy M Pawlik; Patrick Pessaux; Walter Ricciardi; Steven Schwaitzberg; Paresh Shah; Joseph Szokol; Mark Talamini; Ricardo Torres; Alessandro Triboldi; Suthep Udomsawaengsup; Federica Valsecchi; Jean-Nicolas Vauthey; Michael Wallace; Steven D Wexner; Michael Zinner; Nader Francis
Journal:  Ann Surg       Date:  2021-07-01       Impact factor: 12.969

2.  Impact of the COVID-19 Pandemic on Patient-Reported Outcomes of Breast Cancer Patients and Survivors.

Authors:  Claudia A Bargon; Marilot C T Batenburg; Lilianne E van Stam; Dieuwke R Mink van der Molen; Iris E van Dam; Femke van der Leij; Inge O Baas; Miranda F Ernst; Wiesje Maarse; Nieke Vermulst; Ernst J P Schoenmaeckers; Thijs van Dalen; Rhodé M Bijlsma; Danny A Young-Afat; Annemiek Doeksen; Helena M Verkooijen
Journal:  JNCI Cancer Spectr       Date:  2020-11-05

3.  Resource requirements for reintroducing elective surgery during the COVID-19 pandemic: modelling study.

Authors:  A J Fowler; T D Dobbs; Y I Wan; R Laloo; S Hui; D Nepogodiev; A Bhangu; I S Whitaker; R M Pearse; T E F Abbott
Journal:  Br J Surg       Date:  2021-01-27       Impact factor: 6.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.